)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Vimta Labs
Vimta Labs (524394) investor relations material
Vimta Labs Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary30 Oct, 2026
Executive summary
Q2 FY27 total income rose 9.9% YoY to ₹1,148.87 million; EBITDA grew 10.5% to ₹408 million and PAT rose 3.5% to ₹206.14 million.
H1 FY27 total income increased 11.8% to ₹2,278 million, with EBITDA up 13.2% to ₹819 million and PAT up 7.3% to ₹416.56 million.
The Board approved unaudited Q2 and H1 results on October 30, 2026; the statutory auditor issued an unmodified limited review report.
Financial highlights
Q2 revenue from operations was ₹1,119.83 million versus ₹1,018.48 million; other income was ₹29.04 million.
Q2 EBITDA margin was 35.5%; PBT was ₹275.25 million versus ₹262.74 million, and basic EPS was ₹4.61 versus ₹4.50.
H1 revenue from operations was ₹2,210.57 million versus ₹1,994.12 million; PBT rose to ₹558.63 million from ₹515.35 million.
H1 EBITDA margin was 36%; PAT margin was 18.3%, and basic EPS was ₹9.32 versus ₹8.71.
Outlook and guidance
Management expects CRADS and clinical research to improve in Q3 and Q4 as active proposals convert; no quarter-specific forecasts were provided.
Medium-term FY28 targets remain INR 700 crore turnover and a 35%-36% EBITDA margin; the top-line ambition implies 20%-25% CAGR.
Biologics may take a couple of years to become significant; management targets a 1:1 revenue-to-investment return around year three, potentially year two with faster progress.
Medium-term EBITDA margin correction of 100-200 bps is expected, mainly from biologics mix; near-term margins are not expected to change significantly.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vimta Labs
- Turnover fell and losses emerged, while GLP certification strengthened export prospects.524394
Q4 96/97 - Recession drove a Rs 219.81 lakh loss as new inspection services offered growth potential.524394Q4 97/98
- Returned to profit and cleared IDBI term debt through a one-time settlement.524394Q4 99/00
- Record turnover and higher profit, with equipment upgrades and export growth in focus.524394Q4 00/01
- Turnover surged 75%, with record exports and expansion plans supporting the outlook.524394Q4 01/02
- Revenue rose 81%, exports surged, and a fivefold capacity expansion was planned.524394Q4 03/04
- FY03 growth surged as exports expanded and lab capacity investment accelerated.524394Q4 02/03
- Net profit rose 66% as exports surged and major lab expansion advanced.524394Q4 04/05
- Capacity-constrained growth drove expansion, with FY06/07 revenue targeted at Rs.90–100 crore.524394Q4 05/06
Next Vimta Labs earnings date
Q3 26/2714 Feb, 2027
Vimta Labs
Next Vimta Labs earnings date
Q3 26/2714 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Vimta Labs Limited is an Indian company that provides contract research and testing services across various sectors, including pharmaceuticals, food, agriculture, and environmental science. The company offers a range of analytical and research services, such as clinical research, bioanalytical testing, environmental monitoring, food safety analysis, and microbiological testing. Serving both domestic and international clients, Vimta Labs supports quality assurance and regulatory compliance for products and services across multiple industries. The company is headquartered in Hyderabad, India, and its shares are listed on the BSE.